Who makes BI 1387446 200 μg?

BI 1387446 200 μg is developed by Boehringer Ingelheim.

What development phase is BI 1387446 200 μg in?

BI 1387446 200 μg is in Phase 1.

What are the side effects of BI 1387446 200 μg?

Common side effects include Fatigue, Hypertension, Bradycardia, Cataract, Haemorrhoidal haemorrhage, Asthenia.

Last reviewed 2026-04-20 · How we verify

BI 1387446 200 μg

Boehringer Ingelheim · Phase 1 active Small molecule Quality 20/100

At a glance

Generic name	BI 1387446 200 μg
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Fatigue
Hypertension
Bradycardia
Cataract
Haemorrhoidal haemorrhage
Asthenia
Axillary pain
Face oedema
Oedema peripheral
Pain
Hyperbilirubinaemia
Oral candidiasis

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BI 1387446 200 μg CI brief — competitive landscape report
BI 1387446 200 μg updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI